0.21
+0.0088(+4.49%)
Currency In USD
| Previous Close | 0.2 |
| Open | 0.2 |
| Day High | 0.22 |
| Day Low | 0.2 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.15 |
| Volume | 4.66M |
| Average Volume | 17.92M |
| Market Cap | 5.37M |
| PE | -0.07 |
| EPS | -3.06 |
| Moving Average 50 Days | 0.26 |
| Moving Average 200 Days | 0.73 |
| Change | 0.01 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $1.63 as of June 30, 2025 at a share price of $0.205. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $1.14 as of June 30, 2025 at a share price of $0.205.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
GlobeNewswire Inc.
Jun 17, 2025 4:26 PM GMT
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offeri
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
GlobeNewswire Inc.
Jun 17, 2025 1:00 PM GMT
$452.5 million in total milestone payments$2.5 million in near-term paymentsDouble-digit royalties on future net product sales3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (N
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
GlobeNewswire Inc.
Jun 13, 2025 12:00 PM GMT
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team